The last patient has completed the final visit in the Phase 3 PROOF-HD trial testing oral pridopidine for Huntington’s disease. That means that the study’s main placebo-controlled part is done, according to Prilenia Therapeutics, pridopidine’s developer, which sponsored the nearly 18-month-long trial. Now, the first data are…
Columns
I am sitting up in a hospital bed, trying to write this week’s column. I have an IV in my left arm that is attached to a bag full of antibiotics and steroids. As I start to bring my hand to where the needle is held in place by medical…
Thirteen years ago, my good friend Matt Ellison and I started to form what is now the Huntington’s Disease Youth Organization (HDYO). Matt and I both grew up with a parent who had Huntington’s disease (HD), so our mission with the nonprofit was to support, educate, and…
The other day, I heard what every husband wants to hear from his wife: “Honey, I love you, but you’re being ridiculous.” The day had started off uneventfully. It was a Saturday morning, and I woke up early to watch a soccer game on TV. The earlier the better, since…
The biopharmaceutical UCB and Aitia have joined forces to accelerate the development of a novel Huntington’s disease treatment. The collaboration will harness Aitia’s artificial intelligence (AI) technology to identify new targets and therapies for Huntington’s that will be further validated using UCB’s expertise in treatment research and…
My marriage has always been a partnership. I have strengths where my wife, Jill, has weaknesses, and vice versa — until Huntington’s disease (HD) started affecting her mental state and abilities, that is. Jill, who was diagnosed with HD in 2018, likes to say that the…
I recently watched a webinar hosted by the Huntington’s Disease Society of America that highlighted the new Roche/Genentech clinical study, GENERATION HD2 (NCT05686551), which is testing tominersen in people with Huntington’s disease (HD). I was enthused to hear all of the questions from the community that…
Using machine learning, a form of artificial intelligence, researchers were able to cluster people with Huntington’s disease into three groups based on the speed at which the disease progresses, a study showed. “Machine learning approaches such as this could be considered for application in real-world clinical practice to support…
As John Lennon once sang, “Life is what happens to you while you’re busy making other plans.” Well, life happened — again. At the end of February, my wife, Jill, and I had planned to go to Capitol Hill in Washington, D.C., to lobby several congressmen as part…
Enrollment is underway in a Phase 2 clinical trial testing Roche’s therapeutic candidate tominersen in people with early manifest Huntington’s disease and those in the prodromal phase of the disease, when hallmark disease symptoms are not yet present. The study, dubbed GENERATION HD2 (NCT05686551), aims…
Recent Posts
- What caregiver burnout is really about — and what you can do about it
- Oral Huntington’s treatment aims to slow disease progression
- Accepting help from my loved one with HD is a lesson in partnership
- Understanding how Huntington’s disease affects my cognition
- Guest Voice: We hold onto hope while fighting for new treatments
- Top 5 Huntington’s disease news stories of 2025
- Another year means treasuring more moments of shared joy
- Faulty cellular waste disposal system may drive Huntington’s: Study
- What the holidays mean when living with Huntington’s disease
- $12M grant will back first trial of stem cell therapy for Huntington’s